CPMV — Mosaic Immunoengineering Balance Sheet
0.000.00%
Annual balance sheet for Mosaic Immunoengineering, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 0.226 | 0.221 | 0.156 | 0.115 | 0.004 |
| Net Total Receivables | 0 | — | — | — | — |
| Prepaid Expenses | |||||
| Total Current Assets | 0.269 | 0.261 | 0.18 | 0.142 | 0.02 |
| Total Assets | 0.269 | 0.261 | 0.18 | 0.142 | 0.02 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 2.33 | 3.92 | 4.73 | 5.54 | 6.03 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Liabilities | 3.07 | 5.15 | 6.05 | 6.93 | 7.5 |
| Non Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | -2.8 | -4.88 | -5.87 | -6.79 | -7.48 |
| Total Liabilities & Shareholders' Equity | 0.269 | 0.261 | 0.18 | 0.142 | 0.02 |
| Total Common Shares Outstanding | |||||
| Total Preferred Shares Outstanding |